MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-19-2025
Vivos Therapeutics Operating Income 2011-2026 | VVOS
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Vivos Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.2 M | -17.3 M | -25 M | -20.4 M | -12 M | -10.6 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -10.6 M | -25 M | -16.1 M |
Quarterly Operating Income Vivos Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.73 M | -4.86 M | -3.92 M | - | -2.64 M | -1.94 M | -3.78 M | - | -3.64 M | -4.52 M | -5 M | - | -5.41 M | -6.96 M | -6.82 M | - | -5.5 M | -4.06 M | -3.41 M | - | -1.82 M | -1.42 M | -2.56 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.42 M | -6.96 M | -4.06 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Abiomed
ABMD
|
230 M | - | - | $ 17.2 B |  USA |
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
-5.13 M | $ 9.57 | 0.1 % | $ 687 M |  Israel |
 |
Alphatec Holdings
ATEC
|
-136 M | $ 22.65 | -0.15 % | $ 3.24 B | USA |
 |
AxoGen
AXGN
|
-3.29 M | $ 33.63 | 0.78 % | $ 1.49 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
Apyx Medical Corporation
APYX
|
-17.3 M | $ 3.5 | 1.16 % | $ 121 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 3.66 | -3.56 % | $ 136 M |  France |
 |
Electromed
ELMD
|
9.66 M | $ 28.9 | -0.41 % | $ 244 M | USA |
 |
Bio-Rad Laboratories
BIO
|
269 M | $ 323.76 | 1.47 % | $ 9.13 B | USA |
 |
BioSig Technologies
BSGM
|
-12.9 M | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
2.6 B | $ 97.6 | -0.79 % | $ 144 B | USA |
 |
CONMED Corporation
CNMD
|
200 M | $ 43.07 | -2.56 % | $ 1.33 B | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Bruker Corporation
BRKR
|
253 M | $ 54.12 | 3.12 % | $ 8.06 K | USA |
 |
Abbott Laboratories
ABT
|
6.82 B | $ 125.84 | -0.27 % | $ 219 B | USA |
 |
InMode Ltd.
INMD
|
113 M | $ 14.47 | 1.47 % | $ 1.15 B | Israel |
 |
IRIDEX Corporation
IRIX
|
-10 M | $ 1.16 | -2.94 % | $ 18.7 M | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
-156 M | - | -10.19 % | $ 1.99 M | USA |
|
LENSAR
LNSR
|
-10.7 M | $ 11.6 | -0.6 % | $ 134 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
Orthofix Medical
OFIX
|
-84.6 M | $ 15.77 | -2.65 % | $ 601 M |  Curacao |
 |
Second Sight Medical Products
EYES
|
-24.7 M | - | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
Align Technology
ALGN
|
608 M | $ 172.23 | 0.97 % | $ 12.9 B | USA |
 |
Accuray Incorporated
ARAY
|
7.84 M | $ 0.89 | -0.47 % | $ 91.5 M | USA |
 |
IRadimed Corporation
IRMD
|
22 M | $ 98.81 | -1.19 % | $ 1.25 B | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
-19.7 M | $ 15.06 | -1.63 % | $ 407 M | USA |
 |
FONAR Corporation
FONR
|
5.31 M | $ 18.56 | 0.02 % | $ 122 M | USA |
 |
Sintx Technologies
SINT
|
-13.4 M | $ 3.78 | -1.32 % | $ 14.1 M | USA |
 |
Sensus Healthcare
SRTS
|
8.09 M | $ 4.82 | 8.8 % | $ 78.6 M | USA |
 |
Globus Medical
GMED
|
166 M | $ 94.0 | -0.66 % | $ 12.8 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
28.4 M | $ 13.69 | -1.23 % | $ 1.05 B | USA |
 |
Stryker Corporation
SYK
|
3.69 B | $ 369.46 | 0.61 % | $ 141 B | USA |